InvestorsHub Logo

DD8

Followers 10
Posts 1737
Boards Moderated 0
Alias Born 08/14/2013

DD8

Re: None

Monday, 06/18/2018 10:18:20 AM

Monday, June 18, 2018 10:18:20 AM

Post# of 290029
Some facts and info from AB regarding TRTC's competition:
"At the closing prices of C$9.68 for GTI and C$4.69 for MedMen, the two sport market caps of US$1.03 billion and US$1.65 billion, respectively, based on fully-diluted shares."
"MedMen disclosed that in Q1 (its fiscal Q3), it generated sales of US$7.22 million that resulted in an operating loss of US$15.5 million. In the first three quarters of its fiscal year ending June 30th, the company reported sales of US$10.6 million and an operating loss of US$29.5 million, using over US$33 million to fund its operations. In contrast, GTI reported Q1 sales of US$10.9 million, up 261% from Q1 in 2017, with an operating loss of US$1.4 million. For all of 2017, it reported sales of US$16.5 million, with an operating loss of US$4.3 million and a use of US$4.3 million to fund its operations".
"We think that the valuations the market is awarding these new issues is generating some interest among investors in the broader space, including not only iAnthus but also others, like CannaRoyalty, Liberty Health Sciences, MPX Bioceutical and TerraTech."
https://mailchi.mp/newcannabisventures/investors-warm-up-to-direct-us-cannabis-companies-and-12-stories-from-new-cannabis-ventures
https://www.forbes.com/sites/alanjbrochstein/2018/06/17/cannabis-investors-embrace-green-thumb-industries-after-avoiding-medmen/#6dfc46055e76